Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Decrypting a Collagen’s Role in Schizophrenia

By Drug Discovery Trends Editor | March 14, 2016

Cortical neurons (red) form few inhibitory synapses (green) in the absence of collagen XIX (left), but synapse formation is restored by a signaling peptide derived from the protein's C-terminal region (right). Credit: Su et al., 2016A small peptide generated from a collagen protein may protect the brain from schizophrenia by promoting the formation of neuronal synapses, according to a paper published in The Journal of Cell Biology. The study, “Collagen-Derived Matricryptins Promote Inhibitory Nerve Terminal Formation in the Developing Neocortex” by Jianmin Su and colleagues, may lead to new approaches to treating the mental disorder.
 
The collagen family of extracellular matrix proteins performs numerous functions in the brain, and mutations in several family members cause neurological diseases in humans. How collagen XIX promotes normal brain function is unknown, but loss of the gene encoding this collagen has been linked to familial schizophrenia.
 
A team of researchers led by Michael Fox at Virginia Tech Carilion Research Institute has been closely examining collagen XIX. They found that collagen XIX-deficient mice display a number of schizophrenia-related symptoms, including an abnormal startle response and an increased susceptibility to seizures. Schizophrenia has previously been linked to defects in a particular type of interneuron. This interneuron dampens neuronal activity in the brain’s cortex by forming inhibitory synapses with the cell bodies of other neurons. These inhibitory synapses were lost in collagen XIX-deficient mice.
 
Like similar types of collagen, collagen XIX can be cleaved by extracellular protease enzyme to generate a small signaling peptide called a matricryptin. Jianmin Su and colleagues found that this peptide was sufficient to rescue the formation of inhibitory synapses in neuronal cultures prepared from collagen XIX-deficient mice, apparently by binding and activating a cell adhesion receptor called integrin α5β1.
 
Fox and colleagues now want to learn more about how collagen XIX’s matricryptin fragment promotes synapse formation. “We also want to investigate whether the peptide holds any therapeutic potential for any diseases that result for malformed or malfunctioning cortical interneurons,” Fox says.
 
Source: Rockefeller University


Filed Under: Drug Discovery

 

Related Articles Read More >

TransCelerate CEO Janice Chang wants trials to become part of routine care
STEERLife’s FragMelt platform manufactures drugs with heat sensitive active ingredient 
S&P report highlights Big Pharma’s concentration risk amid pre-JPM deal flurry
Eli Lilly in the Drug Discovery & Development Pharma 50
Lilly Phase 3b trial shows roughly 40-fold higher combined arthritis and weight-loss response
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2026 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE